Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel A Zaballos

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Molecular Endocrinology (Baltimore, Md.)|November 20, 2012
FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesisMiguel A Zaballos, Pilar Santisteban
The Journal of Endocrinology|August 26, 2017
Key signaling pathways in thyroid cancerMiguel A Zaballos, Pilar Santisteban
Molecular Endocrinology (Baltimore, Md.)|January 19, 2008
Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cellsMiguel A Zaballos, Bibian Garcia, Pilar Santisteban
Molecular Endocrinology (Baltimore, Md.)|July 16, 2005
DARPP-32 (dopamine and 3',5'-cyclic adenosine monophosphate-regulated neuronal phosphoprotein) is essential for the maintenance of thyroid differentiationCustodia García-Jiménez, Miguel A Zaballos, Pilar Santisteban
Oncotarget|July 8, 2016
β-catenin signaling is required for RAS-driven thyroid cancer through PI3K activationAna Sastre-Perona, Garcilaso Riesco-Eizaguirre, Miguel A Zaballos, et al.
Molecular Endocrinology (Baltimore, Md.)|February 4, 2012
DARPP-32 is required for MAPK/ERK signaling in thyroid cellsAna Chocarro-Calvo, Miguel A Zaballos, Pilar Santisteban, et al.
Endocrine-Related Cancer|April 13, 2019
Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancerMiguel A Zaballos, Adrián Acuña-Ruiz, Marta Morante, et al.
Journal of Visualized Experiments : Jove|September 10, 2019
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in MiceJulia Ramirez-Moya, León Wert-Lamas, Adrián Acuña-Ruiz, et al.
Cellular and Molecular Life Sciences : CMLS|September 3, 2022
Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancerMiguel A Zaballos, Adrián Acuña-Ruiz, Marta Morante, et al.
European Urology|May 13, 2026
Expanding Bevacizumab-Erlotinib Therapy Through Fumarate Hydratase Deficiency Screening and Drug Target Pathway Analysis in Papillary Morphology Metastatic Renal Cell CarcinomaJavier de Nicolás-Hernández, Carlos Valdivia, Alicia Arenas, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Molecular Endocrinology (Baltimore, Md.)|November 20, 2012
FOXO1 controls thyroid cell proliferation in response to TSH and IGF-I and is involved in thyroid tumorigenesisMiguel A Zaballos, Pilar Santisteban
The Journal of Endocrinology|August 26, 2017
Key signaling pathways in thyroid cancerMiguel A Zaballos, Pilar Santisteban
Molecular Endocrinology (Baltimore, Md.)|January 19, 2008
Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cellsMiguel A Zaballos, Bibian Garcia, Pilar Santisteban
Molecular Endocrinology (Baltimore, Md.)|July 16, 2005
DARPP-32 (dopamine and 3',5'-cyclic adenosine monophosphate-regulated neuronal phosphoprotein) is essential for the maintenance of thyroid differentiationCustodia García-Jiménez, Miguel A Zaballos, Pilar Santisteban
Oncotarget|July 8, 2016
β-catenin signaling is required for RAS-driven thyroid cancer through PI3K activationAna Sastre-Perona, Garcilaso Riesco-Eizaguirre, Miguel A Zaballos, et al.
Molecular Endocrinology (Baltimore, Md.)|February 4, 2012
DARPP-32 is required for MAPK/ERK signaling in thyroid cellsAna Chocarro-Calvo, Miguel A Zaballos, Pilar Santisteban, et al.
Endocrine-Related Cancer|April 13, 2019
Regulators of the RAS-ERK pathway as therapeutic targets in thyroid cancerMiguel A Zaballos, Adrián Acuña-Ruiz, Marta Morante, et al.
Journal of Visualized Experiments : Jove|September 10, 2019
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in MiceJulia Ramirez-Moya, León Wert-Lamas, Adrián Acuña-Ruiz, et al.
Cellular and Molecular Life Sciences : CMLS|September 3, 2022
Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancerMiguel A Zaballos, Adrián Acuña-Ruiz, Marta Morante, et al.
European Urology|May 13, 2026
Expanding Bevacizumab-Erlotinib Therapy Through Fumarate Hydratase Deficiency Screening and Drug Target Pathway Analysis in Papillary Morphology Metastatic Renal Cell CarcinomaJavier de Nicolás-Hernández, Carlos Valdivia, Alicia Arenas, et al.
Pageof 2